Mark Erlander PhD

Mark Erlander has more than 18 years of experience directing and leading research and development for gene discovery, with a strong focus on molecular diagnostics.

Since 2012, Dr. Erlander has also served as Chief Scientific Officer of Gensignia, Inc., a lung cancer diagnostics company. Prior to joining Trovagene, Dr. Erlander was chief scientific officer at bioTheranostics, a bioMerieux company. Previously, Dr. Erlander was a group leader and subsequently a research fellow at the R.W. Johnson Pharmaceutical Research Institute (Johnson & Johnson). He was also an assistant member and postdoctoral fellow at The Scripps Research Institute in the Department of Molecular Biology.